Interleukin-2 mastering regulation in cancer and autoimmunity

Annals of the New York Academy of Sciences

Volumn 1107, Issue , 2007, Pages 239-250

  Montero, Enrique ^a   Alonso, Livan ^a   Perez, Rolando ^a   Lage, Agustin ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Autoimmunity; Cancer; Immunoregulation; Immunotherapy; Interleukin 2

Indexed keywords

INTERLEUKIN 2; AUTOANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER RESEARCH; CONFERENCE PAPER; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; TUMOR IMMUNITY; ANIMAL; ARTICLE; DRUG EFFECT; HUMAN; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

MUS;

ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; NEOPLASMS;

EID: 34648847075     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1381.026     Document Type: Conference Paper

References (65)

1. LANGMAN, R.E. & M. COHN. 2000. Self-nonself discrimination revisited. Introduction. Semin. Immunol. 12: 159-162.
2. BURNET, F.M. 1959. The Clonal Selection Theory of Adquired Immunity. Vanderbilt University Press. Nashville, TN.
3. COHEN, I.R. 1992. The cognitive principle challenges clonal selection. Immunol. Today 13: 441-444.
4. BURNET, F.M. 1970. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13: 1-27.
5. PREHN, R.T. & J.M. MAIN. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18: 769-778.
6. COUTINHO, A. 2002. Immunology at the crossroads. As decades of research have resulted in few clinical applications, it is time to think about new research strategies to understand the workings of the immune system. EMBO Rep. 3: 1008-1011.
7. ZINKERNAGEL, R.M. 2001. Immunity against solid tumors? Int. J. Cancer 93: 1-5.
8. COUTINHO, A. et al. 2001. Regulatory T cells: the physiology of autoreactivity in dominant tolerance and "quality control" of immune responses. Immunol. Rev. 182: 89-98.
9. KAPPLER, J.W. et al. 1988. Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex. Nature 332: 35-40.
10. COUTINHO, A. et al. 1984. From an antigen-centered, clonal perspective of immune responses to an organism-centered, network perspective of autonomous activity in a self- referential immune system. Immunol. Rev. 79: 151-168.
11. COHEN, I.R. 1986. Regulation of autoimmune disease physiological and therapeutic. Immunol. Rev. 94: 5-21.
12. SAKAGUCHI, S., T. TAKAHASHI & Y. NISHIZUKA. 1982. Study on cellular events in post-thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis. J. Exp. Med. 156: 1577-1586.
13. GERSHON, R.K. 1975. A disquisition on suppressor T cells. Transplant. Rev. 26: 170-185.
14. OHKI, H. et al. 1987. Tolerance induced by thymic epithelial grafts in birds. Science 237: 1032-1035.
15. MONTERO, E. et al. 2000. Tumor-specific immunotherapy based on dominant models of natural tolerance. Med. Hypotheses 54: 531-536.
16. COHEN, I.R. 1992. The cognitive paradigm and the immunological homunculus. Immunol. Today 13: 490-494.
17. GONZALEZ, G. et al. 2002. Autoimmunization to epidermal growth factor, a component of the immunological homunculus. Autoimmun. Rev. 1: 89-95.
18. RAZ, I. et al. 2001. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358: 1749-1753.
19. SAKAGUCHI, S. 2004. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531-562.
20. MONTERO, E. et al. 2004. Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies. J. Autoimmun. 23: 1-7.
21. GERSHON, R.K. & K. KONDO. 1971. Infectious immunological tolerance. Immunology 21: 903-914.
22. SMITH, K.A. 1980. T-cell growth factor. Immunol. Rev. 51: 337-357.
23. LENARDO, M.J. 1991. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 353: 858-861.
24. DAI, Z. et al. 1998. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J. Immunol. 161: 1659-1663.
25. DAI, Z. et al. 1999. The role of the common cytokine receptor gamma-chain in regulating IL-2-dependent, activation-induced CD8+ T cell death. J. Immunol. 163: 3131-3137.
26. SERREZE, D.V. & E.H. LEITER. 1988. Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. J. Immunol. 140: 3801-3807.
27. SERREZE, D.V., K. HAMAGUCHI & E.H. LEITER. 1989. Immunostimulation circumvents diabetes in NOD/Lt mice. J. Autoimmun. 2: 759-776.
28. GUTIERREZ-RAMOS, J.C. et al. 1990. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature 346: 271-274.
29. KLEBB, G. et al. 1996. Interleukin-2 is indispensable for development of immunological self-tolerance. Clin. Immunol. Immunopathol. 81: 282-286.
30. GILLIS, S., A.E. GILLIS & C.S. HENNEY. 1981. Monoclonal antibody directed against interleukin 2. I. Inhibition of T lymphocyte mitogenesis and the in vitro differentiation of alloreactive cytolytic T cells. J. Exp. Med. 154: 983-988.
31. SAKAGUCHI, S. & N. SAKAGUCHI. 1989. Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease. J. Immunol. 142: 471-480.
32. SETOGUCHI, R. et al. 2005. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201: 723-735.
33. KUNDIG, T.M. et al. 1993. Immune responses in interleukin-2-deficient mice. Science 262: 1059-1061.
34. KNEITZ, B. et al. 1995. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice. Eur. J. Immunol. 25: 2572-2577.
35. SADLACK, B. et al. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261.
36. KRAMER, S., A. SCHIMPL & T. HUNIG. 1995. Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene. J. Exp. Med. 182: 1769-1776.
37. STEIGER, J. et al. 1995. IL-2 knockout recipient mice reject islet cell allografts. J. Immunol. 155: 489-498.
38. WELLS, A.D. et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5: 1303-1307.
39. DAI, Z., B.T. KONIECZNY & F.G. LAKKIS. 2000. The dual role of IL-2 in the generation and maintenance of CD8+ memory T cells. J. Immunol. 165: 3031-3036.
40. NORDLUND, J.J. et al. 1983. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Dermatol. 9: 689-696.
41. FISHMAN, P. et al. 1993. Vitiligo autoantibodies are effective against melanoma. Cancer 72: 2365-2369.
42. COULIE, P.G. et al. 1994.Anewgene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180: 35-42.
43. ROSENBERG, S.A. & D.E. WHITE. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19: 81-84.
44. OVERWIJK, W.W. et al. 1999. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl. Acad. Sci. USA 96: 2982-2987.
45. NANDA, N.K. & E.E. SERCARZ. 1995. Induction of anti-self-immunity to cure cancer. Cell 82: 13-17.
46. PARDOLL, D.M. 1999. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA 96: 5340-5342.
47. GONZALEZ, G. et al. 2007. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum. Vaccin. 3: 8-13.
48. GONZALEZ, G. et al. 1996. Induction of immune recognition of self epidermal growth factor (EGF): effect on EGF biodistribution and tumor growth. Vaccine Res. 5: 233-244.
49. CROMBET, T. et al. 2004. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J. Clin. Oncol. 22: 1646-1654.
50. NORTH, R.J. & I. BURSUKER. 1984. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1 + 2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J. Exp. Med. 159: 1295-1311.
51. ROSENBERG, S.A. et al. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907-913.
52. MATZINGER, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12: 991-1045.
53. KUMAR, V. & E. SERCARZ. 1995. Self-determinant selection and selective regulation. Chem. Immunol. 60: 1-19.
54. TURK, M.J. et al. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200: 771-782.
55. CURIEL, T.J. et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
56. NISHIKAWA, H. et al. 2005. Accelerated chemically induced tumor development mediated by CD4+CD25 +regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA 102: 9253-9257.
57. AHMADZADEH, M. & S.A. ROSENBERG. 2006. IL-2 administration increases CD4+ CD25(hi) Foxp3t regulatory T cells in cancer patients. Blood. 107: 2409-2414.
58. TAKEUCHI, T. et al. 2004. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model. BJU Int. 94: 171-176.
59. NELSON, B.H. 2004. IL-2, regulatory T cells, and tolerance. J. Immunol. 172: 3983-3988.
60. DANNULL, J. et al. 2005. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115: 3623-3633.
61. BOYMAN, O. et al. 2006. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311: 1924-1927.
62. BALKWILL, F. & A. MANTOVANI. 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539-545.
63. ATTIA, P. et al. 2005. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23: 6043-6053.
64. GOGAS, H. et al. 2006. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354: 709-718.
65. MOYA, G. et al. 2002. Isolation and characterization of modified species of a mutated (Cys125 -Ala) recombinant human interleukin-2. J. Chromatogr. A 971: 129-142.